ArticleLeukemia2015
Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
C M Lucas et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this paperpooled itcites it